Results 21 to 30 of about 22,288 (223)

Predominantly hemorrhagic choroidal neovascular lesion from exsudative age-related macular degeneration treated with intravitreal ranibizumab therapy

open access: yesRevista Brasileira de Oftalmologia, 2013
The authors relate a predominantly hemorrhagic choroidal neovascular lesion from neovascular. Age-related macular degeneration patient case treated with intravitreal ranibizumab therapy.
Miguel Hage Amaro, Aaron Brock Holler
doaj   +1 more source

New Frontiers in Retina: highlights of the 2020 angiogenesis, exudation and degeneration symposium

open access: yesInternational Journal of Retina and Vitreous, 2020
We summarize the most important findings presented at the 2020 angiogenesis, exudation and degeneration symposium in five topic areas: (1) epidemiology of retinal vascular disease and macular degeneration; (2) dry AMD and geographic atrophy; (3 ...
Carmen A. Puliafito, Charles C. Wykoff
doaj   +1 more source

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab

open access: yesInternational Journal of Ophthalmology, 2017
AIM: To report the change in visual acuity and central macular thickness (CMT) following treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration (nAMD) with suboptimum response to ranibizumab ...
Rachel Hui Fen Lim   +2 more
doaj   +1 more source

Prevalence of age-related macular degeneration in Nakuru, Kenya: a cross-sectional population-based study. [PDF]

open access: yes, 2013
BACKGROUND: Diseases of the posterior segment of the eye, including age-related macular degeneration (AMD), have recently been recognised as the leading or second leading cause of blindness in several African countries.
Peto, Tunde; id_orcid   +24 more
core   +1 more source

FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice

open access: yesCell Reports, 2017
Pathological neovascularization, a leading cause of blindness, is seen in retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration.
Zhongjie Fu   +12 more
doaj   +1 more source

The chronic care for age-related macular degeneration study (CHARMED): Study protocol for a randomized controlled trial

open access: yesTrials, 2011
Background Neovascular age-related macular degeneration is the leading cause of irreversible blindness in people 50 years of age or older in the developed world.
Held Ulrike   +4 more
doaj   +1 more source

The estimated prevalence and incidence of late stage age related macular degeneration in the UK [PDF]

open access: yes, 2012
BACKGROUND: UK estimates of age related macular degeneration (AMD) occurrence vary. AIMS: To estimate prevalence, number and incidence of AMD by type in the UK population aged ≥50 years.
Fletcher, AE   +11 more
core   +1 more source

THE CORRELATION BETWEEN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AND CLINICAL ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

open access: yes, 2021
Purpose: The aim of the current study was to investigate the correlation between the pretreatment aqueous level of vascular endothelial growth factor (VEGF) and clinical activity in neovascular age-related macular degeneration.Methods: Patients with ...
0000-0001-9645-3837   +34 more
core   +1 more source

CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD. [PDF]

open access: yes, 2009
Age-related macular degeneration (AMD) is a prevalent cause of blindness in Western societies. Variants in the genes encoding complement factor H (CFH), complement component 3 (C3) and age-related maculopathy susceptibility 2 (ARMS2) have repeatedly been
Weber, Bernhard H. F.   +68 more
core   +1 more source

Brolucizumab-induced retinal vasculitis – An Indian perspective

open access: yesIndian Journal of Ophthalmology. Case Reports, 2022
The case of retinal vasculitis in a one-eyed elderly diabetic female after use of brolucizumab injection (second dose) for neovascular age-related macular degeneration.
Manpreet Brar   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy